The newly appointed U.S. team includes the following:

• Robert Sgroi, head of marketing and sales
• Ian Clarke, head of market access
• Dr. Val Nassiri, head of medical affairs

The team's main goal is to advance ITM's radiopharmaceutical pipeline and prepare for U.S. market entry, sales, and distribution of ITM's pipeline of candidates for targeted radionuclide therapies, the company said. Those candidates include ITM-11 (Lu-177 edotreotide), ITM's candidate for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). ITM-11 is currently being evaluated in two phase III clinical studies.